|1.||He, Jiao: 1 article (11/2011)|
|2.||Zhang, Yongmin: 1 article (11/2011)|
|3.||Sun, Wenji: 1 article (11/2011)|
|4.||Zhu, Sha: 1 article (11/2011)|
|5.||Liang, Jinru: 1 article (11/2011)|
|6.||Zhao, Wenna: 1 article (11/2011)|
|7.||Loria, Paola: 1 article (01/2002)|
|8.||Concari, Mauro: 1 article (01/2002)|
|9.||Bertolotti, Marco: 1 article (01/2002)|
|10.||Guicciardi, Maria Eugenia: 1 article (01/2002)|
08/01/1993 - "The reproductive toxicity of taurohyodeoxycholic acid (3 alpha, 6 alpha-dihydroxy-5-beta-cholanoyl-2-amino-ethyl-sulfonic acid, THDCA, Io, Praxis, CAS 2958-04-5), a new synthetized biliary acid patented in Europe, Japan and the United States for prevention and therapy of gallstones and related symptoms, was assayed by performing segment I (fertility and general reproductive performance) and segment II (teratology) studies. "
11/16/2011 - "Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice."
11/16/2011 - "The results suggested that THDCA from Pulvis Fellis Suis has a protective effect in TNBS-induced ulcerative colitis which might be due to its anti-inflammatory activities, and that it may have therapeutic value in the setting of inflammatory bowel disease."
11/16/2011 - "The aim of this study is to evaluate the effect of taurohyodeoxycholic acid (THDCA) isolated from Pulvis Fellis Suis on acute ulcerative colitis model induced by trinitrobenzene sulfonic acid (TNBS) in mice. "
11/16/2011 - "Treatment with THDCA in doses of 25, 50 and 100mg/kg/day and sulfasalazine in a dose of 500 mg/kg/day used as reference for 7 consecutive days after the induction of colitis, significantly decreased colonic MPO activity, TNF-α, IL-6 serum levels and the expression of COX-2 in colon compared with TNBS induced ulcerative colitis model group. "
|3.||Chromosome Aberrations (Chromosome Abnormalities)
|4.||Liver Diseases (Liver Disease)
09/01/1999 - "These data could partially explain the therapeutic mechanism of UDCA, TUDCA, and THDCA in chronic cholestatic liver disease. "
01/01/2000 - "Taurohyodeoxycholic acid could be therapeutic in cholestatic liver disease by inducing P4503A; we can hypothesize that an associated P-glycoprotein expression might facilitate biliary excretion of toxic taurochenodeoxycholic acid accumulated in the liver during cholestasis."
|5.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
|2.||Bile Acids and Salts (Bile Acids)
|5.||Interleukin-6 (Interleukin 6)